2 Biotech Stocks ARK Invest Bought in June
Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months.
On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs. Should you put them in your own portfolio?
Data source: ARK Funds.
Source Fool.com
